Literature DB >> 2535693

Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.

A M Deffie1, J K Batra, G J Goldenberg.   

Abstract

The relationship between DNA topoisomerase II activity and drug resistance was studied in cloned cell lines of Adriamycin (ADR)-sensitive and -resistant P388 leukemia; drug resistant P388/ADR/3 (clone 3) and P388/ADR/7 (clone 7) cells are 5- and 10-fold more resistant to ADR than the sensitive cell line P388/4 (Cancer Res., 46: 2978, 1986). Topoisomerase II catalytic activity in crude nuclear extracts was reduced in drug-resistant cells as determined qualitatively by decatenation of kDNA. Using the centrifugal method fo quantitative analysis, topoisomerase II catalytic activity (mean +/- SE) was 81 +/- 10 units/mg total nuclear protein in sensitive cells, 29 +/- 2 units/mg total nuclear protein in resistant clone 3 cells, and 16 +/- 2 units/mg total nuclear protein in resistant clone 7 cells; these differences were highly significant (P less than 0.005). Similarly, quantitative analysis of DNA cleavage activity using 3' 32P-end-labeled pBR322 restriction fragments showed that drug-stimulated topoisomerase II cleavage activity in nuclear extracts from sensitive cells was approximately 1.7- and 2.9-fold greater than that from resistant clone 3 and 7 cells, respectively. Western blot analysis of nuclear extracts from the three cell lines using antibody against the C-terminal half of recombinant-prepared human topoisomerase II polypeptide revealed reduced immunoreactivity of topoisomerase II protein in the drug-resistant cells. These data suggest that reduced topoisomerase II activity in resistant cells, which may represent quantitative reduction of the enzyme, may be another property contributing to multifactorial drug resistance in these cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535693

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma.

Authors:  Helena Brizova; Marketa Kalinova; Lenka Krskova; Marcela Mrhalova; Roman Kodet
Journal:  Virchows Arch       Date:  2010-04-24       Impact factor: 4.064

Review 2.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Characterization of an etoposide-resistant human small-cell lung cancer cell line.

Authors:  K Minato; F Kanzawa; K Nishio; K Nakagawa; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Influences of "spasmolytic powder" on pgp expression of Coriaria Lactone-kindling drug-resistant epileptic rat model.

Authors:  Lei Chen; Peimin Feng; Yaohua Li; Dong Zhou
Journal:  J Mol Neurosci       Date:  2012-12-20       Impact factor: 3.444

Review 5.  ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.

Authors:  Jiexin Deng; Jie Shao; John S Markowitz; Guohua An
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

Review 6.  The challenge of drug resistance in cancer treatment: a current overview.

Authors:  Michail Nikolaou; Athanasia Pavlopoulou; Alexandros G Georgakilas; Efthymios Kyrodimos
Journal:  Clin Exp Metastasis       Date:  2018-05-24       Impact factor: 5.150

7.  Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Authors:  Cleo E Rolle; Rajani Kanteti; Mosmi Surati; Suvobroto Nandi; Immanuel Dhanasingh; Soheil Yala; Maria Tretiakova; Qudsia Arif; Todd Hembrough; Toni M Brand; Deric L Wheeler; Aliya N Husain; Everett E Vokes; Ajit Bharti; Ravi Salgia
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

8.  Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

Authors:  Eugen Ruckhäberle; Thomas Karn; Lars Hanker; Regine Gätje; Dirk Metzler; Uwe Holtrich; Manfred Kaufmann; Achim Rody
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

9.  The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR phenotype.

Authors:  J J Killion; R Radinsky; Z Dong; R Fishbeck; P Whitworth; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

10.  Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.

Authors:  S de Jong; J G Zijlstra; N H Mulder; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.